Welch Investments LLC Purchases 501 Shares of Johnson & Johnson (JNJ)
Welch Investments LLC raised its position in Johnson & Johnson (NYSE:JNJ) by 1.4% during the third quarter, HoldingsChannel.com reports. The fund owned 35,608 shares of the company’s stock after acquiring an additional 501 shares during the period. Johnson & Johnson comprises approximately 3.2% of Welch Investments LLC’s investment portfolio, making the stock its 16th biggest position. Welch Investments LLC’s holdings in Johnson & Johnson were worth $4,629,000 at the end of the most recent quarter.
A number of other hedge funds have also recently bought and sold shares of JNJ. Abbrea Capital LLC increased its position in Johnson & Johnson by 1.3% in the third quarter. Abbrea Capital LLC now owns 33,855 shares of the company’s stock worth $4,401,000 after buying an additional 441 shares in the last quarter. Putnam FL Investment Management Co. purchased a new stake in shares of Johnson & Johnson during the third quarter worth about $5,138,000. IBM Retirement Fund grew its position in shares of Johnson & Johnson by 1.3% during the third quarter. IBM Retirement Fund now owns 66,873 shares of the company’s stock worth $9,568,000 after purchasing an additional 844 shares in the last quarter. Gs Investments Inc. grew its position in shares of Johnson & Johnson by 32.0% during the third quarter. Gs Investments Inc. now owns 4,435 shares of the company’s stock worth $577,000 after purchasing an additional 1,075 shares in the last quarter. Finally, Blue Chip Partners Inc. grew its position in shares of Johnson & Johnson by 2.7% during the third quarter. Blue Chip Partners Inc. now owns 67,697 shares of the company’s stock worth $8,801,000 after purchasing an additional 1,760 shares in the last quarter. 65.53% of the stock is currently owned by institutional investors.
JNJ has been the subject of several research analyst reports. Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $152.28 target price for the company in a research report on Tuesday, January 23rd. Credit Suisse Group set a $154.00 target price on Johnson & Johnson and gave the stock an “outperform” rating in a research report on Thursday, October 19th. Royal Bank of Canada increased their target price on Johnson & Johnson from $144.00 to $147.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 18th. Stifel Nicolaus increased their target price on Johnson & Johnson from $142.00 to $145.00 and gave the stock a “hold” rating in a research report on Wednesday, January 24th. Finally, Citigroup increased their target price on Johnson & Johnson from $140.00 to $149.00 and gave the stock a “buy” rating in a research report on Monday, October 23rd. Four analysts have rated the stock with a sell rating, eight have issued a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. Johnson & Johnson currently has a consensus rating of “Hold” and an average price target of $146.16.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, January 23rd. The company reported $1.74 EPS for the quarter, beating analysts’ consensus estimates of $1.72 by $0.02. Johnson & Johnson had a return on equity of 27.80% and a net margin of 1.70%. The company had revenue of $20.20 billion during the quarter, compared to analyst estimates of $20.08 billion. During the same period in the prior year, the company earned $1.58 earnings per share. The firm’s revenue was up 11.5% on a year-over-year basis. equities analysts anticipate that Johnson & Johnson will post 8.08 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 2.59%. The ex-dividend date of this dividend is Monday, February 26th. Johnson & Johnson’s payout ratio is presently 861.54%.
ILLEGAL ACTIVITY WARNING: “Welch Investments LLC Purchases 501 Shares of Johnson & Johnson (JNJ)” was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://theolympiareport.com/2018/02/15/welch-investments-llc-purchases-501-shares-of-johnson-johnson-jnj.html.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.